Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer. Pancreatic cancer remains a challenge in ...

ST316, a first-in-class antagonist of the interaction between β-catenin and its co-activator BCL9, has demonstrated promising results in the phase 1 dose-escalation ST316-101 study (NCT05848739) for ...

ST316 is a first-in-class antagonist of β-catenin and its co-activator, BCL9, that is designed to selectively shut down the Wnt/β-catenin signaling pathway. The Phase 1 Dose Escalation study enrolled ...

ST316 is a first-in-class antagonist of β-catenin and its co-activator, BCL9, that is designed to selectively shut down the Wnt/β-catenin signaling pathway. The Phase 1 Dose Escalation study ...

ST316 is a first-in-class peptide antagonist of the interaction between β-catenin and its co-activator, BCL9, a complex responsible for driving oncogene expression in multiple cancers where aberrant ...

The binding of BCL9 to β‐catenin can be specifically abrogated by the point mutation D164A. Future analysis of mice carrying this mutation will give us precise information about the relevance of the ...

Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

Effect of BCL9/BCL9L inhibition–derived Th1 cells on dendritic cells–mediated antigen presentation in hepatocellular carcinoma and on the efficacy of CAR-T immunotherapy. This is an ASCO Meeting ...

The B-cell lymphoma 9/B-cell lymphoma 9-like (BCL9/BCL9L) is a critical transcription co-factor of β-catenin. Suppression of Bcl9 inhibits tumor growth in mouse models of colorectal cancer (CRC). Here ...

We explored the cell interaction between NT and Bcl9-KD groups. The TGFβ-TGFβR and EGFR-NRG1 binding between receptor and ligand was obvious in CAF/CT26 subgroups, revealing a cross-talk between the ...